SILVERBACK THERAPEUTICS INC (SBTX) Forecast, Price Target & Analyst Ratings
NASDAQ:SBTX • US82835W1080
5.87 USD
+0.06 (+1.03%)
Last: Nov 8, 2022, 04:30 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SILVERBACK THERAPEUTICS INC (SBTX).
Forecast Snapshot
Consensus Price Target
$5.10
-13.12% Downside
Next Earnings Forecast
Release DateNov 22, 2022
PeriodQ4 / 2022
EPS Estimate-$0.35
Revenue Estimate
ChartMill Buy Consensus
43.33%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$5.10
Upside
-13.12%
From current price of $5.87 to mean target of $5.10, Based on 6 analyst forecasts
Low
$5.05
Median
$5.10
High
$5.25
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
6 analysts have analysed SBTX and the average price target is 5.1 USD. This implies a price decrease of -13.12% is expected in the next year compared to the current price of 5.87.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
43.33%
SBTX was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about SBTX.
In the previous month the buy percentage consensus was at a similar level.
SBTX was analyzed by 6 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2021-11-12 | SVB Leerink | Maintains | Outperform |
| 2021-08-16 | SVB Leerink | Maintains | Outperform |
| 2021-05-27 | JonesTrading | Initiate | Buy |
| 2021-05-17 | SVB Leerink | Maintains | Outperform |
| 2021-04-06 | SVB Leerink | Maintains | Outperform |
| 2021-03-30 | Stifel | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateNov 22, 2022
PeriodQ4 / 2022
EPS Estimate-$0.35
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q47.48%
Number of Analysts4
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
SBTX is expected to report earnings on 11/22/2022. The consensus EPS estimate for the next earnings is -0.35 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | |||||
| EBITDA YoY % growth | -17.84M | -23.53M -31.89% | -32.28M -37.19% | -88.801M -175.10% | N/A 21.75% | N/A -4.50% | N/A -3.50% | N/A 3.92% | N/A 0.40% | |
| EBIT YoY % growth | -18.32M | -24.07M -31.39% | -32.92M -36.77% | -89.584M -172.13% | N/A 25.23% | N/A -10.37% | N/A -5.75% | N/A 9.86% | N/A 8.06% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.56 -10.08% | N/A 26.29% | N/A -10.81% | N/A -4.88% | N/A 9.65% | N/A 7.84% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 22 | |
|---|---|
| EPS Q2Q % growth | -0.35 47.48% |
| Revenue Q2Q % growth | |
| EBITDA Q2Q % growth | N/A |
| EBIT Q2Q % growth | -12.491M 46.86% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
4.57%
EPS Next 5 Year
5.17%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
6.20%
EBIT Next 5 Year
4.27%
SILVERBACK THERAPEUTICS INC / SBTX Forecast FAQ
What is the price target for SBTX stock?
6 analysts have analysed SBTX and the average price target is 5.1 USD. This implies a price decrease of -13.12% is expected in the next year compared to the current price of 5.87.
When does SILVERBACK THERAPEUTICS INC (SBTX) report earnings?
SILVERBACK THERAPEUTICS INC (SBTX) will report earnings on 2022-11-22, after the market close.
Can you provide the consensus estimates for SILVERBACK THERAPEUTICS INC next earnings?
The consensus EPS estimate for the next earnings of SILVERBACK THERAPEUTICS INC (SBTX) is -0.35 USD and the consensus revenue estimate is 0 USD.
What is the consensus rating for SILVERBACK THERAPEUTICS INC (SBTX) stock?
The consensus rating for SILVERBACK THERAPEUTICS INC (SBTX) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.